Abstract
Coronaviruses contain an unusually long (27–32,000 ribonucleotide) positive sense RNA genome that is polyadenylated at the 3’ end and capped at the 5’ end. In addition to the genome, infected cells contain subgenomic mRNAs that form a 3’ co-terminal nested set with the genome. In addition to their common 3’ ends, the genome and the subgenomic mRNAs contain an identical 5’ leader sequence. The transcription mechanism that coronaviruses use to produce subgenomic mRNA is not known and has been the subject of speculation since sequencing of the subgenomic mRNAs showed they must arise by discontinuous transcription. The current model called leader-primed transcription has subgenomic mRNAs transcribed directly from genome-length negative strands. It was based on the failure to find in Coronavirus infected cells subgenome-length negative strands or replication intermediates containing subgenome-length negative strands. Clearly, these structures exist in infected cells and are transcriptionally active. We proposed a new model for Coronavirus transcription which we called 3’ discontinuous extension of negative strands. This model predicts that subgenome-length negative strands would be derived directly by transcription using the genome RNA as a template. The subgenome-length templates would contain the common 5’ leader sequence and serve as templates for the production of subgenomic mRNAs. Our findings include showing that: 1. Replication intermediates (RIs) containing subgenome-length RNA exist in infected cells and are separable from RIs with genome-length templates. The RFs with subgenome-length templates are not derived by RNase treatment of RIs with genome-length templates. 2. The subgenome-length negative strands are formed early in infection when RIs are accumulating and the rate of viral RNA synthesis is increasing exponentially. 3. Subgenome-length negative strands contain at their 3’ ends a complementary copy of the 72 nucleotide leader RNA that is found in the genome only at their 5’ end. 4. RIs with subgenomic templates serve immediately as templates for transcription of subgenomic mRNAs. Because subgenomic mRNAs are not replicated, i.e., copied into negative strands that in turn are used as templates for subgenomic mRNA synthesis, we propose that the subgenome-length negative strands must arise directly by transcription of the genome and acquire their common 3’ anti-leader sequence after polymerase jumping from the intergenic regions to the leader sequence at the 5’ end of the genome. This would make negative strand synthesis discontinuous and subgenomic mRNA synthesis continuous, which is the opposite of what was proposed in the leader primed model.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Download to read the full chapter text
Chapter PDF
References
Baric, R. S., Stohlman, S. A., Lai, M. M. C, 1983, Characterization of replicative intermediate RNA of mouse hepatitis virus: presence of leader RNA sequences on nascent chains, J. Virol. 48:633.
Brian, D. A., Chang, R.-Y., Hofmann, M. A., Sethna, P. B., 1994, Role of subgenomic minus-strand RNA in Coronavirus replication, Arch. Virol. (Suppl.) 9:173–180.
Chang, R. Y., Krishnan, R., and Brian, D. A., 1996, The UCUAAAC promoter motif is not required for high frequency leader recombination in bovine Coronavirus defective interfering RNA, J. Virol. 70:2720–2729.
Komissarova, N., and Kashlev, M, 1997, Transcription arrest: Escherichia coli RNA polymerase translocates backward, leaving the 3’ end of the RNA intact and extruded, Proc. Natl. Acad. Sci. USA 94:1755–1760.
Lai, M. M. C, Patton, C. D., and Stohlman, S. A., 1982, Replication of mouse hepatitis virus: negative-stranded RNA and replicative form RNA are of genome length, J. Virol. 44:487–492.
Lai, M. M. C., 1990, Coronavirus-organization, replication and expression of genome, Annu. Rev. Microbiol. 44:303–333.
Makino, S., Joo, M., and Makino, J. K., 1991, A system for study of Coronavirus mRNA synthesis: a regulated, expressed subgenomic defective interfering RNA results from intergenic site insertion, J. Virol. 65:6031–6041.
Masters, P. S., Koetzner, C. A., Kerr, C. A., and Heo, Y., 1994, Optimization of targeted RNA recombination and mapping of a novel nucleocapsid gene mutation in the Coronavirus mouse hepatitis, J. Virol. 68:328–337.
Nudler, E., Mustaev, A., Lukhtanov, E., and Goldfarb, A., 1997, The RNA-DNA hybrid maintains the register of transcription by preventing backtracking on RNA polymerase, Cell. 89:33–41.
Sawicki, S. G, and Sawicki, D. L., 1990. Coronavirus transcription: subgenomic mouse hepatitis virus replicative intermediates function in RNA synthesis, J. Virol 64:1050–1056.
Sawicki, S. G.and Sawicki, D. L., 1995, Coronaviruses use discontinuous extension for synthesis of subgenome-length negative strands, in: Corona and Related Viruses (P. J. Talbot and G. A. Levy, eds) Plenum Press, New York, pp. 499–505.
Sethna, P. B., Hung, S-L., and Brian, D. A., 1989, Coronavirus subgenomic minus-strand RNAs and the potential for mRNA replicons, Proc. Natl. Acad. Sci. USA 86:5626–5630.
Stillman, E. A., and Whitt, M. A., 1997, Mutational analysis of the intergenic dinucleotide and the transcriptional start sequence of vesicular stomatitis virus (VSV) define sequences required for efficient termination and initiation of VSV transcripts, J. Virol. 71:2127–2137.
van der Most, R. G., de Groot, R. J., and Spaan, W. J. W., 1994, Subgenomic RNA synthesis directed by a synthetic defective interfering RNA of mouse hepatitis virus: a study of Coronavirus transcription initiation, J. Virol. 68:3656–3666.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Sawicki, S.G., Sawicki, D.L. (1998). A New Model for Coronavirus Transcription. In: Enjuanes, L., Siddell, S.G., Spaan, W. (eds) Coronaviruses and Arteriviruses. Advances in Experimental Medicine and Biology, vol 440. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5331-1_26
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5331-1_26
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7432-9
Online ISBN: 978-1-4615-5331-1
eBook Packages: Springer Book Archive